title: Efficacy of chelation therapy to remove aluminium intoxication.
abstract: There is a distinct correlation between aluminium (Al) intoxication and neurodegenerative diseases (ND). We demonstrated how patients affected by ND showing Al intoxication benefit from short-term treatment with calcium disodium ethylene diamine tetraacetic acid (EDTA) (chelation therapy). Such therapy further improved through daily treatment with the antioxidant Cellfood. In the present study we examined the efficacy of long-term treatment, using both EDTA and Cellfood. Slow intravenous treatment with the chelating agent EDTA (2 g/10 mL diluted in 500 mL physiological saline administered in 2 h) (chelation test) removed Al, which was detected (using inductively coupled plasma mass spectrometry) in urine samples collected from patients over 12 h. Patients that revealed Al intoxication (expressed in μg per g creatinine) underwent EDTA chelation therapy once a week for ten weeks, then once every two weeks for a further six or twelve months. At the end of treatment (a total of 22 or 34 chelation therapies, respectively), associated with daily assumption of Cellfood, Al levels in the urine samples were analysed. In addition, the following blood parameters were determined: homocysteine, vitamin B12, and folate, as well as the oxidative status e.g. reactive oxygen species (ROS), total antioxidant capacity (TAC), oxidized LDL (oxLDL), and glutathione. Our results showed that Al intoxication reduced significantly following EDTA and Cellfood treatment, and clinical symptoms improved. After treatment, ROS, oxLDL, and homocysteine decreased significantly, whereas vitamin B12, folate and TAC improved significantly. In conclusion, our data show the efficacy of chelation therapy associated with Cellfood in subjects affected by Al intoxication who have developed ND.
authors.affiliation: Department of Biomedical Sciences for Health, University of the Study of Milan, Milan, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Fulgenzi
authors.affiliation: Department of Biomedical, Surgical and Dental Sciences University of the Study of Milan, Haematology-Oncology and BMT Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Rachele
authors.initials: R
authors.lastname: De Giuseppe
authors.affiliation: Department of Biomedical, Surgical and Dental Sciences University of the Study of Milan, Haematology-Oncology and BMT Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Fabrizia
authors.initials: F
authors.lastname: Bamonti
authors.affiliation: Department of Biomedical Sciences for Health, University of the Study of Milan, Milan, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Vietti
authors.affiliation: Department of Biomedical Sciences for Health, University of the Study of Milan, Milan, Italy.
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Ferrero
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000535:Aluminum / Q000097:blood / Q000506:poisoning* / Q000652:urine; D000596:Amino Acids / Q000009:adverse effects / Q000627:therapeutic use; D015913:Chelation Therapy / Q000009:adverse effects*; D057487:Enzyme Therapy; D004798:Enzymes / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000009:adverse effects / Q000627:therapeutic use; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology; D013431:Sulfates / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000596:Amino Acids; C532683:Cellfood; D004798:Enzymes; D008903:Minerals; D013431:Sulfates; D000535:Aluminum
keywords: Aluminium; Chelation therapy; Intoxication